|
Deep Vein Thrombosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
According to inclusion and exclusion standards, from October 2017 to June 2018, 30 consecutive patients of aneurysmal subarachnoid hemorrhage admitted to Intensive Care Unit, Department of Neurosurgery at Xuanwu Hospital, were given remote ischemic conditioning 5 times intervention to each patient within 7 days, and blood coagulation function testing, including prothrombin activity (PTA), prothrombin time (PT), activated partial prothrombin time (APTT), fibrinogen (Fib), D-dimer, and thromboelastogram (TEG, including R, K, Angle, MA, EPL, LY30, A, CI, G, and A30) were performed for each patient before and after the RIC intervention, as well as venous ultrasound monitoring before and after the RIC intervention for detection of deep vein thrombosis (DVT).
|
31605259 |
2020 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This molecular mechanism might be the main cause for DVT in patients with this dysfunctional prothrombin gene.
|
29382582 |
2018 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The outcome variables were the incidence rate of DVT, activated partial thromboplastin time (APTT), prothrombin time (PT), and D-dimer; subcutaneous hematoma; and other reported outcomes.RevMan5.2. software was adopted for the meta-analysis.
|
29636064 |
2018 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
To determine whether monitoring would enhance its benefit-risk profile, we examined whether peak and trough prothrombin time (PT) values measured in 3797 rivaroxaban-treated patients included in the EINSTEIN DVT and PE studies correlated with subsequent recurrent VTE and major bleeding.
|
30121419 |
2018 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We documented that age, acute infection, prothrombin time (PT), D-dimer, erythrocyte sedimentation rate, blood platelets, and anticoagulation were significantly associated with the occurrence of DVT ( P < .05).
|
30198321 |
2018 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The proband experienced severe bleeding episodes during her pregnancy, which required treatment with prothrombin complex concentrates, and then pulmonary embolism and deep-vein thrombosis at 28 days postpartum, which required treatment with LMWH and fresh frozen plasma.
|
27975099 |
2017 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A long journey preceded deep vein thrombosis recurrence after 12 months of rivaroxaban use in a 59-year-old obese man homozygous for prothrombin 20210A mutation.
|
28079536 |
2017 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis.
|
26908601 |
2016 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To determine if the deep vein thrombosis was of genetic origin, a peripheral blood DNA sample was analysed for the presence of the three most frequent mutations associated with thrombotic events: factor V Leiden (1691G>A), prothrombin (20210G>A) and methylene tetrahydrofolate reductase (677C>T).
|
24627725 |
2014 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Prothrombin gene polymorphism was found in 6% of APS patients and in 2.5% of healthy subjects (p=0.21), and 13% of patients with DVT (p=0.14).
|
24093662 |
2014 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The FII A19911G variant was more prevalent in patients with DVT and with PL compared with controls; however, these differences were not statistically significant.
|
25316662 |
2014 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Deep vein thrombosis (DVT) has a strong inherited predisposition that is partly explained by the strong genetic risk factors such as mutations in factor V, prothrombin, antithrombin III, protein C and S genes.
|
25091233 |
2014 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We present the case of a male-to-female transsexual person in her 20s requesting hormone therapy in the setting of a history of a deep venous thrombosis and pulmonary embolus and carrying the prothrombin G20210A gene mutation.
|
23807525 |
2014 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FVL and FII mutation were not significantly associated with RVO at the multivariate analysis in all patients, although data suggest that FVL and FII mutation may have a differential effect on RVO in the subgroups of patients with DVT and DVT plus PE patients.
|
23306310 |
2013 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of prothrombin G20210A polymorphism and of elevated factor VIII levels was significantly higher in patients with DVT and DVT/PE than in controls, but not in those with isolated PE, whereas factor V Leiden polymorphism was associated with isolated DVT but not with DVT/PE or isolated PE.
|
22422337 |
2012 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found that besides to the well-established aforementioned sequence variations of FV and Prothrombin, the FSAP Marburg I (FSAP-MI) polymorphism was significantly associated with the development of DVTs (1.65 (1.16-2.34) OR (95% CI)) and recurrent thromboembolic events (DVT and PE) (2.13 (1.35-3.36) OR (95% CI)).
|
22421107 |
2012 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Patients identified preoperatively as having a personal or familial history of DVT and/or PE were referred for hemostatic serum and genetic tests, including % antithrombin III activity (ATIII), protein C and protein S activities, APC resistance, Factor V gene (Leiden) mutations, prothrombin gene mutations, lupus anticoagulant antibody presence, cardiolipin antibody presence, phosphatidyl antibody presence, β2-glycoprotein antibody presence, and serum homocysteine and lipoprotein(a) levels The frequencies of varying abnormalities were identified and compared to the prevalence reported in the literature.
|
20824408 |
2011 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
If the proband had VTE and factor V Leiden (FVL) and/or prothrombin (PT)20210A, the HR for DVT was 2.77 (95%CI 1.21-4.82) in the carriers overall, and 5.54 (95%CI 3.20-187.00) in those homozygous or double heterozygous for FVL and PT20210A.
|
21833444 |
2011 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A formerly unknown vena cava atresia with severe bilateral deep vein thrombosis and concomitant heterozygous prothrombin (factor II) gene mutation (G20210A) was diagnosed during the hospital stay.
|
21885950 |
2011 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the general population, Prothrombin G20210A heterozygotes had1.3 (95% CI:0.6-2.9) fold risk for VTE, 0.6 (0.2-2.0) for DVT, 1.7(0.6-4.8) for PE, 1.5(1.1-2.1) for IHD, 1.7(1.1-2.7) for MI, 1.1(0.6-1.9) for ICVD, and 1.1(0.5-2.1) for IS compared to non-carriers.
|
19524925 |
2010 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of present study was to investigate the prevalence of factor V Leiden (FVL) c.1691G>A, prothrombin g.20210G>A and methylenetetrahydrofolate reductase (MTHFR) c.677C>T in deep vein thrombosis (DVT) patients and their possible association with DVT in western Iran.
|
20479641 |
2010 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study investigated whether the clinical manifestation of VTE, the extension of deep vein thrombosis (DVT) and the presence of transient risk factors at the time of the first VTE, differed among patients with mutations (97 with FVLeiden; 33 with prothrombin G20210A) and in 109 patients without thrombophilia.
|
18796457 |
2010 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Patients with recurrent DVT or a family history of DVT were significantly (p<0.0001) more likely to have the prothrombin mutation than other DVT patients.
|
19920886 |
2009 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We studied the association between the 1601G/A polymorphism, FSAP activity, FSAP antigen, Factor VIIa (FVIIa), prothrombin fragment 1+2 (F1+2), and C-reactive protein (CRP) in plasmas of 170 patients suspected for DVT.
|
18394684 |
2008 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Partial HELLP syndrome in pregnancy complicated by recurrent deep vein thromboses and palmar skin lesions in a patient with prothrombin gene 20210a mutation and antiphospholipid antibodies: an unusual case.
|
17610004 |
2008 |